Development of Novel Indole-Based Covalent Inhibitors of TEAD as Potential Antiliver Cancer Agents
Journal of Medicinal Chemistry · 26.09.2024 · 67 (18) · 16270-16295
DOI: 10.1021/acs.jmedchem.4c00925 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 13.09.2024. Verfasst von Chen Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida 32610, United States. Hauptthemen laut MEDLINE: Antineoplastic Agents, Liver Neoplasms, Carcinoma, Hepatocellular, Indoles. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: NIH HHS, State of Florida, Congressionally Directed Medical Research Programs.
Abstract (Originalsprache)
Abnormal activation of the YAP transcriptional signaling pathway drives proliferation in many hepatocellular carcinoma (HCC) and hepatoblastoma (HB) cases. Current treatment options often face resistance and toxicity, highlighting the need for alternative therapies. This article reports the discovery of a hit compound C-3 from docking-based virtual screening targeting TEAD lipid binding pocket, which inhibited TEAD-mediated transcription. Optimization led to the identification of a potent and covalent inhibitor CV-4-26 that exhibited great antitumor activity in HCC and HB cell lines in vitro, xenografted human HCC, and murine HB in vivo. These outcomes signify the potential of a highly promising therapeutic candidate for addressing a subset of HCC and HB cancers. In the cases of current treatment challenges due to high upregulation of YAP-TEAD activity, these findings offer a targeted alternative for more effective interventions against liver cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida 32610, United States.
- Department of Pathology and Laboratory Medicine, School of Medicine, Tulane University, New Orleans, Louisiana 70112, United States.
- Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, Florida 32610, United States.
- Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida 32610, United States.
- UF Health Cancer Center, University of Florida, Gainesville, Florida 32610, United States.
- UF Institute of Genetics, University of Florida, Gainesville, Florida 32610, United States.
ORCID-Profile: Wei Zhou, Chenglong Li
Förderung
- NIH HHS
- State of Florida
- Congressionally Directed Medical Research Programs
- National Institute on Alcohol Abuse and Alcoholism
- National Institutes of Health
- National Science Foundation
- Bodor Professorship Fund
Zitieren
APA
Zhou, C., Sun, C., Zhou, W., Tian, T., Schultz, D. C., Wu, T., Yu, M., Wu, L., Pi, L., & Li, C. (2024). Development of Novel Indole-Based Covalent Inhibitors of TEAD as Potential Antiliver Cancer Agents. Journal of Medicinal Chemistry, 67(18), 16270-16295. https://doi.org/10.1021/acs.jmedchem.4c00925
Vancouver
Zhou C, Sun C, Zhou W, Tian T, Schultz DC, Wu T, et al. Development of Novel Indole-Based Covalent Inhibitors of TEAD as Potential Antiliver Cancer Agents. Journal of Medicinal Chemistry. 2024;67(18):16270-16295. doi:10.1021/acs.jmedchem.4c00925
BibTeX
@article{Zhou2024,
author = {Zhou, Chen and Sun, Chunbao and Zhou, Wei and Tian, Tian and Schultz, Daniel C and Wu, Tong and Yu, Mu and Wu, Lizi and Pi, Liya and Li, Chenglong},
title = {Development of Novel Indole-Based Covalent Inhibitors of TEAD as Potential Antiliver Cancer Agents},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {18},
pages = {16270--16295},
doi = {10.1021/acs.jmedchem.4c00925}
}
EUVIMED